Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma

(MedPage Today) -- CHICAGO -- Adding the immune checkpoint inhibitor nivolumab (Opdivo), rather than brentuximab vedotin (Adcetris), to a standard chemotherapy backbone reduced the risk of disease progression or death in newly diagnosed adults...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news